Purchase this article with an account.
Crystal Su Algenio, Mark Qiao, Sabrina Chow, James F McDonnell, Jay Perlman, Ping Bu; Therapeutic Effects of Paeoniflorin Following Retinal Ischemic-Reperfusion Injury. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5913.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Retinal ischemia-reperfusion presents a major common cause of visual impairment and blindness in the industrialized world. Current treatment options for retinal ischemic diseases are very limited. Paeoniflorin is a monoterpene glycoside derived from the root of Paeonia lactiflora Pallas. Paeoniflorin has been shown in previous studies to exhibit various pharmacological properties including anti-inflammatory, antioxidant, and immunoregulatory activities, making it a potential therapeutic agent against degenerative pathologies. The purpose of this study is to determine if Paeoniflorin attenuates retinal degeneration by minimizing oxidative and inflammatory stress in retinal ischemic-reperfusion injury.
C57BL/6 mice were assigned to one of two groups: vehicle- treated or Paeoniflorin-treated retinal ischemic injury mice. Retinal ischemia was induced by transient elevation of intraocular pressure for 45 minutes. Vehicle (PBS) or Paeoniflorin (20 mg/kg in PBS) was injected intraperitoneally once a day for 5 days following retinal ischemia. Scotopic electroretinography (ERG) was recorded before induction of retinal ischemia, and 7 days after inducing ischemia. The amplitude and times of the scotopic a- and b-waves were quantified and statistically compared among Paeoniflorin treatment and control groups.
Before treatment, scotopic ERG a- and b-wave amplitudes were 392 ± 75 μV and 831 ± 62 μV, respectively, in the control group, and 396 ± 43 μV and 818 ± 75 μV, respectively, in the Paeoniflorin group. Following ischemic-reperfusion injury, ERG a-wave amplitudes were 180 ± 13 μV in the control group and 307 ± 61 μV in the Paeoniflorin group (p < 0.005). Post-ischemic insult ERG b- wave amplitudes were 320 ± 48 μV in the control group and 583 ± 74 μV in the Paeoniflorin group (p < 0.005). Seven days after ischemic-reperfusion injury, Paeoniflorin treatment of mice was proven to attenuate ischemic induced loss of retinal function compared to vehicle treated mice, as shown by the preservation of ERG a- and b-wave amplitudes.
Conclusions: Paeoniflorin treatment of mice showed attenuation of retinal degeneration by preservation of ERG a-and b-wave amplitudes following ischemic-reperfusion injury. Our preliminary data suggests that Paeoniflorin may have therapeutic value in the management of retinal ischemic diseases.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only